Evidence map›Paper›PMID 41952042›Full record

ArticleOral diseases2026

CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study.

Simone Liguori, Noemi Coppola, Elvira Ruoppo, Federica Canfora, Gabriele Mignogna, Ilaria Mormile, Antonia Fiore, Giuseppe Castaldo, Michele Davide Mignogna, Stefania Leuci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Simone LiguoriDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0009-0002-5303-0855
Noemi CoppolaDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0000-0002-0030-3621
Elvira RuoppoDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
Federica CanforaDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0000-0002-4610-6690
Gabriele MignognaDepartment of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
Ilaria MormileDepartment of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.ORCID https://orcid.org/0000-0001-7599-5426
Antonia FioreClinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE, Naples, Italy.
Giuseppe CastaldoClinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE, Naples, Italy.
Michele Davide MignognaDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
Stefania LeuciDepartment of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study evaluated the CD4

methodsThe clinical course of 27 PV patients treated with Rituximab was evaluated after a 32-month median follow-up. CD4

resultsPatients were administered Rituximab as adjuvant therapy: 16 (59%) relapsed while 11 (41%) achieved clinical remission. Higher CD4

conclusionsLower CD4

Indexed as

CD4-Positive T-LymphocytesImmunologic FactorsPemphigusRituximabAdultAgedAntigens, CD20B-LymphocytesCD4 Lymphocyte CountFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesAntigens, CD20Immunologic FactorsRituximabflow cytometrypemphigus vulgarisrelapseRituximabT cells

Identifiers

PMID41952042
PMCPMC13590902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.